180 Life Sciences Corp (ATNF)

[SCModerate]

Current & Future Valuation: From Stocktwits:
"I was looking at a few articles regarding how to put a valuation on clinical-stage biotech- the takeaway points would indicate that ATNF will have a current valuation much larger than $100M when we get the 1st analyst coverage.

One takeaway is a rule of thumb valuation for an approved drug is 3 times peak 1-year sales... then that number is discounted by different % s depending on the current trial stage (which determines the likelihood of eventual approval. (So even drugs that make it through pre-clinical trial into phase 1 trials are assigned often something like 10% of peak 1-year sales.

But the Dupuytren drug should be at least 60-75% based on all of the specific factors... which would rise to 100% once approved. Not sure what peak one-year sales are likely to be on a $5-7 Billion total addressable market... but any modest est put market cap much much higher than $100M for what the current market cap should be.

For example, assigning a $750M peak 1-year sales (which is prob extremely low)... then discounted to take 60% of that amount for the current trial stage (against very low Est)... comes out to $450,000. Then $450M x 3 = $1.3Billion.

So assuming $750M is a realistic peak of 1-year sales for a $5-7Billion total addressable market... this valuation formula would indicate the current market cap should be over $1 Billion, just for Dupuytren. (I guess we will see once the 1St analyst price targets come out ... hopefully any day now).

If this is anywhere in the ballpark of being applied correctly.. it would indicate current valuation should be 13x current levels? Or if looking at future valuation ... over $100 price target if Dupuytren drug is approved (based on a guess of $750M being the peak one year sales).

[Mnhotrodbuilder]

Love this bio setup. World class management team. Nice pipeline with a new pre-trial this year, 2 phase two trials starting and phase 2b/3 results this year. First two trials are grant funded and the third is expected to be as well. Management owns 50% of the company and are not taking salaries so very low cash burn. Looking for good things this year from 180LS.

[Fangster]

I’m with you being long on this one. Sitting on a nice gain now but looking for more on a sell off.

[starkd748]

I'm long ...Could go parabolic

[Fangster]

Who knows when this grows daddy long legs... this company is on to something. I love the convergence of THC/CBD and Biotech AND brilliant proven leadership.

[starkd748]

Parabolic soon

[SuncliffCBDROCKS]

Love this stock.
Looking really good.

[starkd748]

Parabolic time?

[SuncliffCBDROCKS]

See if we can get this to REALLY SQUEEZE.

Looking great.

[SuncliffCBDROCKS]

OH YAH, Love this stock.

[Flanker7]

Looks good, I'm in

[SCModerate]

ATNF Due Diligence -Big Opportunity here

Currently under $80 Million Market Cap, low Float, Management very invested and owns 50-60% of shares, Best Management Team around with proven track records, Huge Pipeline Potential
---------------------
$ATNF (180 Life Sciences) had a prolonged and rocky SPAC process, which caused the price to drop a lot on merge day in Nov. Partly due to stocks rights and partially due to it being misunderstood to be a European Pot Stock (b/c 1 of the 3 companies that formed the current on, was based in Europe and developing synthetic CBD candidate to target arthritis via Anti-TNF properties... discovered by one of the Co-Founders Professor Raphael Mechoulam- a likely 2021 Nobel Prize nominee).

But now that phase is in the rearview mirror and the stock's chart is showing a breakout- and the company is now fully controlled and lead by an insanely accomplished team- I challenge anyone to identify a small-cap team with better expertise or track records).... just read their bios below:
------------------------------------------------

MANAGEMENT TEAM:
Dr James Woody:
Discovered Remicade (J&J acquired for $5 Billion. Sales of $50 Billion+ since approval). Founded Avidia and Proteolix (sold to Amgen). CEO & Founder of Oncomed Pharma. President of Roche Bioscience.

Prof Raphael Mechoulam:
Cannabinoid Pioneer. Discovered the body’s endocannabinoid system. Likely 2021 Nobel Prize Nominee (Won the 2020 Harvey Prize, often precursor award to Nobel).

Prof Sir Marc Feldman: Oxford. Pioneer of anti-TNF therapy (world's biggest drug class, $150 Billion+ by 2025). Lead clinical trial for drug Remicade (J&J acquired for $5 Billion).

Prof Sir Marc Feldman: Oxford. Pioneer of anti-TNF therapy (world's biggest drug class, $150 Billion+ by 2025). Lead clinical trial for drug Remicade (J&J acquired for $5 Billion).
----------------------------------------

PIPELINE PRESENTATION:
Here is a recent presentation (pipeline info and management bios are on slides 3 & 4):
https://d1io3yog0oux5.cloudfront.net/_a92f94aa8ff733cde0d7169f92f7a254/180lifesciences/db/858/7393/pdf/180LS+Corporate+Presentation+-+12.04.2020+v33.pdf

--------------------------------------------------------------
PIPELINE BACKGROUND/ ADDITIONAL INFO:
(Closest Trial has a $4.5B total addressable market size for Drug with the late-stage result later in the year. Earlier Stage Trials have Huge addressable markets (NASH, Arthritis, Ulcerative Colitis, etc). Almost all are grant-funded thanks to the team's reputation and University connections).

ATNF stands for Anti-TNF... the world's largest class of drugs (expected to grow to $150B by 2025). $ATNF Team member, Prof Sir Marc Feldman (Oxford) pioneered Anti-TNF therapy. Feldman, along with $ANTF president Dr. James Woody used this to discover Remicade (which J&J acquired for over $5 Billion).

TNF inhibitor drugs use monoclonal antibodies to treat autoimmune and inflammatory conditions: psoriasis, IBD, asthma, Crohn’s disease, cancers, rheumatoid arthritis, etc.... ie, Enbrel, Humira, Remicade.

Additionally, Cannabinol has been discovered to have natural Anti-TNF properties ... Co-Founder Prof Raphael Mechoulam is a Cannabinoid Pioneer, who Discovered the body’s endocannabinoid system.
--------------------------------
In addition to the strong Anti-TNF platform (Dupuytren, Shoulder Fibrosis, NASH, etc, etc) & the CBD derivative platform (Arthritis & other inflammatory diseases)...
the nicotinic antagonist platform- initially targeting “smoking cessation induced Ulcerative Colitis” is a much larger addressable market than it sounds- considering its estimated this class accounts for up to 30% of UC cases. Also this drug would have competitive advantage of being taken orally (vs biologic shots) with no associated risks.
---------------------------------

Two Recent Articles on Management and Pipeline:

https://cbdtesters.co/2020/12/04/prestigious-harvey-prize-goes-to-raphael-mechoulam-the-godfather-of-cannabis-research/

https://www.biospace.com/article/180-life-sciences-poised-to-break-ground-with-anti-tnf-program/

[SCModerate]

Due Diligence Info

Currently under $80 Million Market Cap, low Float, Management very invested and owns 50-60% of shares, Best Management Team around with proven track records, Huge Pipeline Potential
---------------------
$ATNF (180 Life Sciences) had a prolonged and rocky SPAC process, which caused the price to drop a lot on merge day in Nov. Partly due to stocks rights and partially due to it being misunderstood to be a European Pot Stock (b/c 1 of the 3 companies that formed the current on, was based in Europe and developing synthetic CBD candidate to target arthritis via Anti-TNF properties... discovered by one of the Co-Founders Professor Raphael Mechoulam- a likely 2021 Nobel Prize nominee).

But now that phase is in the rearview mirror and the stock's chart is showing a breakout- and the company is now fully controlled and lead by an insanely accomplished team- I challenge anyone to identify a small-cap team with better expertise or track records).... just read their bios below:
------------------------------------------------

MANAGEMENT TEAM:
Dr James Woody:
Discovered Remicade (J&J acquired for $5 Billion. Sales of $50 Billion+ since approval). Founded Avidia and Proteolix (sold to Amgen). CEO & Founder of Oncomed Pharma. President of Roche Bioscience.

Prof Raphael Mechoulam:
Cannabinoid Pioneer. Discovered the body’s endocannabinoid system. Likely 2021 Nobel Prize Nominee (Won the 2020 Harvey Prize, often precursor award to Nobel).

Prof Sir Marc Feldman: Oxford. Pioneer of anti-TNF therapy (world's biggest drug class, $150 Billion+ by 2025). Lead clinical trial for drug Remicade (J&J acquired for $5 Billion).

Prof Sir Marc Feldman: Oxford. Pioneer of anti-TNF therapy (world's biggest drug class, $150 Billion+ by 2025). Lead clinical trial for drug Remicade (J&J acquired for $5 Billion).
----------------------------------------

PIPELINE PRESENTATION:
Here is a recent presentation (pipeline info and management bios are on slides 3 & 4):
https://d1io3yog0oux5.cloudfront.net/_a92f94aa8ff733cde0d7169f92f7a254/180lifesciences/db/858/7393/pdf/180LS+Corporate+Presentation+-+12.04.2020+v33.pdf

--------------------------------------------------------------
PIPELINE BACKGROUND/ ADDITIONAL INFO:
(Closest Trial has a $4.5B total addressable market size for Drug with the late-stage result later in the year. Earlier Stage Trials have Huge addressable markets (NASH, Arthritis, Ulcerative Colitis, etc). Almost all are grant-funded thanks to the team's reputation and University connections).

ATNF stands for Anti-TNF... the world's largest class of drugs (expected to grow to $150B by 2025). $ATNF Team member, Prof Sir Marc Feldman (Oxford) pioneered Anti-TNF therapy. Feldman, along with $ANTF president Dr. James Woody used this to discover Remicade (which J&J acquired for over $5 Billion).

TNF inhibitor drugs use monoclonal antibodies to treat autoimmune and inflammatory conditions: psoriasis, IBD, asthma, Crohn’s disease, cancers, rheumatoid arthritis, etc.... ie, Enbrel, Humira, Remicade.

Additionally, Cannabinol has been discovered to have natural Anti-TNF properties ... Co-Founder Prof Raphael Mechoulam is a Cannabinoid Pioneer, who Discovered the body’s endocannabinoid system.
--------------------------------
In addition to the strong Anti-TNF platform (Dupuytren, Shoulder Fibrosis, NASH, etc, etc) & the CBD derivative platform (Arthritis & other inflammatory diseases)...
the nicotinic antagonist platform- initially targeting “smoking cessation induced Ulcerative Colitis” is a much larger addressable market than it sounds- considering its estimated this class accounts for up to 30% of UC cases. Also this drug would have competitive advantage of being taken orally (vs biologic shots) with no associated risks.
---------------------------------

Two Recent Articles on Management and Pipeline:

https://cbdtesters.co/2020/12/04/prestigious-harvey-prize-goes-to-raphael-mechoulam-the-godfather-of-cannabis-research/

https://www.biospace.com/article/180-life-sciences-poised-to-break-ground-with-anti-tnf-program/

[SCModerate]

ATNF Due Diligence Info

Summary:
Currently under $80 Million Market Cap, low Float, Management very invested and owns 50-60% of shares, Best Management Team around with proven track records, Huge Pipeline Potential
---------------------
BACKGROUND:
$ATNF (180 Life Sciences) had a prolonged and rocky SPAC process, which caused the price to drop a lot on merge day in Nov. Partly due to stocks rights and partially due to it being misunderstood to be a European Pot Stock (b/c 1 of the 3 companies that formed the current on, was based in Europe and developing synthetic CBD candidate to target arthritis via Anti-TNF properties... discovered by one of the Co-Founders Professor Raphael Mechoulam- a likely 2021 Nobel Prize nominee).

But now that phase is in the rearview mirror and the stock's chart is showing a breakout- and the company is now fully controlled and lead by an insanely accomplished team- I challenge anyone to identify a small-cap team with better expertise or track records).... just read their bios below:
------------------------------------------------

MANAGEMENT TEAM:
Dr James Woody:
Discovered Remicade (J&J acquired for $5 Billion. Sales of $50 Billion+ since approval). Founded Avidia and Proteolix (sold to Amgen). CEO & Founder of Oncomed Pharma. President of Roche Bioscience.

Prof Raphael Mechoulam:
Cannabinoid Pioneer. Discovered the body’s endocannabinoid system. Likely 2021 Nobel Prize Nominee (Won the 2020 Harvey Prize, often precursor award to Nobel).

Prof Sir Marc Feldman: Oxford. Pioneer of anti-TNF therapy (world's biggest drug class, $150 Billion+ by 2025). Lead clinical trial for drug Remicade (J&J acquired for $5 Billion).

Prof Sir Marc Feldman: Oxford. Pioneer of anti-TNF therapy (world's biggest drug class, $150 Billion+ by 2025). Lead clinical trial for drug Remicade (J&J acquired for $5 Billion).
----------------------------------------

PIPELINE PRESENTATION:
Here is a recent presentation (pipeline info and management bios are on slides 3 & 4):
180 Life Sciences Recent Presentation- Pipeline & Management Bios

--------------------------------------------------------------
PIPELINE BACKGROUND/ ADDITIONAL INFO:
(Closest Trial has a $4.5B total addressable market size for Drug with the late-stage result later in the year. Earlier Stage Trials have Huge addressable markets (NASH, Arthritis, Ulcerative Colitis, etc). Almost all are grant-funded thanks to the team's reputation and University connections).

ATNF stands for Anti-TNF... the world's largest class of drugs (expected to grow to $150B by 2025). $ATNF Team member, Prof Sir Marc Feldman (Oxford) pioneered Anti-TNF therapy. Feldman, along with $ANTF president Dr. James Woody used this to discover Remicade (which J&J acquired for over $5 Billion).

TNF inhibitor drugs use monoclonal antibodies to treat autoimmune and inflammatory conditions: psoriasis, IBD, asthma, Crohn’s disease, cancers, rheumatoid arthritis, etc.... ie, Enbrel, Humira, Remicade.

Additionally, Cannabinol has been discovered to have natural Anti-TNF properties ... Co-Founder Prof Raphael Mechoulam is a Cannabinoid Pioneer, who Discovered the body’s endocannabinoid system.
--------------------------------
In addition to the strong Anti-TNF platform (Dupuytren, Shoulder Fibrosis, NASH, etc, etc) & the CBD derivative platform (Arthritis & other inflammatory diseases)...
the nicotinic antagonist platform- initially targeting “smoking cessation induced Ulcerative Colitis” is a much larger addressable market than it sounds- considering its estimated this class accounts for up to 30% of UC cases. Also this drug would have competitive advantage of being taken orally (vs biologic shots) with no associated risks.
---------------------------------

Two Recent Articles on Management and Pipeline:

Potential Nobel Prize for CBD Discoveries

180 Life Sciences ground breaking Anti-TNF

[Mnhotrodbuilder]

Starting to pick up some steam! Word is still just getting out. Looking for good things from 180 through the end of the year.

[Mnhotrodbuilder]

I agree, 60% shares locked up, lower float and I consider it very undiscovered so far. They have stated no offerings for at least 3 years as their two current trials are grant funded and they expect the next to be as well. They have only been public since 9 Nov. Once they get more PR’s out, with their pipeline and outstanding management they will move on up. Management not taking salaries and are using value of the stock to compensate them down the road. Just liking what I see. I like your average BTW, I’m higher but not worried in long term.

[SuncliffCBDROCKS]

Looks good, been holding over a month and added 1000 more today.
11,000 at 2.43 average.
This can move super fast.

[Mnhotrodbuilder]

Starting to pick up today. Presentation next week.

[ClayTrader]

* * $ATNF Video Chart 12-18-2020 * *

Link to Video - click here to watch the technical chart video

[MADDSTACKER]

News .?

[SuncliffCBDROCKS]

Beautiful, Oh yah.

[Mnhotrodbuilder]

Tons of warrants being picked up today.

[Mnhotrodbuilder]

Interview with the CEO posted on YouTube today. All social media pages are now up. Looking for good things from these guys in the future with their amazing leadership team and proven track record bringing billion dollar products to the market.

[MADDSTACKER]

Lots of warrants bought today ..

[ZimZum]

This shows you can short SPAC’s successfully. What was the symbol for the SPAC prior to the rev split?

[panther14565]

Whats the deal with this one then?